Developments in diagnosis and antileishmanial drugs.
Developments in diagnosis and antileishmanial drugs.
复制标题
DOI：
10.1155/2012/626838
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Singh, Rajni
中科院分区：
文献类型：
--
作者：
Bhargava, Prachi;Singh, Rajni
在被忽视的热带病引起的伤残调整生命年疾病负担中，利什曼病排名第三，是仅次于疟疾的与寄生虫有关的第二大死亡原因；但由于种种原因，它并没有得到应有的重视。利什曼病是由利什曼属原生动物寄生虫引起的一组不同的临床综合征。据估计，88个国家有3.5亿人面临风险，全球皮肤利什曼病发病率为100万至150万例，内脏利什曼病发病率为50万例。早期病例检测的诊断方法的改进和最新的组合化疗方法给对抗这种致命疾病带来了新的希望。利什曼原虫和哺乳动物细胞的细胞生物学差异很大，这种差异延伸到生化水平。这提供了希望，许多寄生虫的蛋白质应该与宿主有足够的不同，可以成功地利用作为药物靶点。本文简要概述了抗利什曼病药物发现和开发的诊断和方法的最新进展。
Leishmaniasis ranks the third in disease burden in disability-adjusted life years caused by neglected tropical diseases and is the second cause of parasite-related deaths after malaria; but for a variety of reasons, it is not receiving the attention that would be justified seeing its importance. Leishmaniasis is a diverse group of clinical syndromes caused by protozoan parasites of the genus Leishmania. It is estimated that 350 million people are at risk in 88 countries, with a global incidence of 1-1.5 million cases of cutaneous and 500,000 cases of visceral leishmaniasis. Improvements in diagnostic methods for early case detection and latest combitorial chemotherapeutic methods have given a new hope for combating this deadly disease. The cell biology of Leishmania and mammalian cells differs considerably and this distinctness extends to the biochemical level. This provides the promise that many of the parasite's proteins should be sufficiently different from hosts and can be successfully exploited as drug targets. This paper gives a brief overview of recent developments in the diagnosis and approaches in antileishmanial drug discovery and development.